European Commission Grants Marketing Authorization to Luspatercept
Leah SherwoodMyelodysplastic Syndromes | March 24, 2023
The European Commission (EC) has granted full Marketing Authorization to luspatercept for the treatment of anemia in adult patients with nontransfusion-dependent beta thalassemia. The centralized Marketing Authorization approves use of luspatercept in all European Union (EU) member states, as well as Norway, Iceland, and Liechtenstein. ...
Advertisement
Advertisement

Advertisement
Advertisement
Editorial Board

Knowledge Hubs

Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia

Trending on MashupMD

ACUTE MYELOID LEUKEMIA

October 12, 2022